AbbVie Inc.
ABBVAbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
Drugs in Pipeline
164
Phase 3 Programs
93
Upcoming Catalysts
18
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
18 upcoming, 5 past
How ABBV's past catalysts played out
Bimatoprost SR
Open-Angle Glaucoma
ABT-333
Chronic Hepatitis C Infection
Ubrogepant
Migraine
Estradiol/Norethindrone Acetate
Endometriosis
Paricalcitol
Chronic Kidney Disease Stage 3 and 4
Dasabuvir
Chronic Hepatitis C Infection
ABT-493/ABT-530
Hepatitis C Virus Infection
Palivizumab
Respiratory Syncytial Virus (RSV)
secukinumab
Psoriasis
Telaprevir
Chronic Hepatitis C Infection
Glecaprevir/Pibrentasvir
Hepatitis C Virus (HCV)
Ubrogepant 100 mg
Migraine
sofosbuvir (SOF)
Chronic Hepatitis C Virus
Vedolizumab
Ulcerative Colitis
Upadacitinib (ABT-494)
Ulcerative Colitis (UC)
etanercept
Moderate to Severe Plaque Psoriasis
ABT-493
Chronic Hepatitis C
OnabotulinumtoxinA
Forehead Lines
Standard of Care
Non-Squamous Non-Small Cell Lung Cancer
AGN-190584
Presbyopia
Topical corticosteroids (TCS)
Atopic Dermatitis
Risankizumab SC
Crohn's Disease
Dalbavancin
Methicillin-Resistant Staphylococcus Aureus
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Acalabrutinib
Chronic Lymphocytic Leukemia
Abatacept
Rheumatoid Arthritis (RA)
Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer
OBV/PTV/r
Chronic Hepatitis C Virus
AGN-151586
Glabellar Lines
Atogepant
Chronic Migraine
Estradiol /norethindrone acetate (E2/NETA)
Heavy Menstrual Bleeding
Bimatoprost (SR)
Open-Angle Glaucoma
Botulinum Toxin Type A
Masseter Muscle Prominence
Best Available Therapy (BAT)
Myelofibrosis (MF)
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)
Irritable Bowel Syndrome With Constipation
ABBV-444
Dry Eye Disease
Linaclotide
Functional Constipation (FC)
Trifluridine/Tipiracil
Metastatic Colorectal Cancer
Navitoclax
Myelofibrosis (MF)
Tocilizumab
Juvenile Idiopathic Arthritis
Armour Thyroid
Hypothyroidism
ABT-874
Plaque Psoriasis
Antidepressant Therapy (ADT)
Major Depressive Disorder
Leuprolide Acetate (LA)
Central Precocious Puberty (CPP)
risankizumab IV
Crohn Disease
Fumaderm
Psoriasis
Fluvoxamine maleate
Obsessive Compulsive Disorder
Open-label Adalimumab
Axial Spondyloarthritis
Sofosbuvir
Chronic Hepatitis C
ombitasvir/paritaprevir/ritonavir, dasabuvir
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
2 DAA
HCV
Topiramate
Migraine
Livmoniplimab
Hepatocellular Carcinoma
Budigalimab
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Cariprazine Flexible Dose
Schizophrenia
ABT-450/r/ABT-267
Hepatitis C Virus Infection
Glecaprevir/Pibrentasvir Adult Formulation
Hepatitis C Virus (HCV)
Elotuzumab
Multiple Myeloma
Glecaprevir/Pibrentasvir (GLE/PIB)
Hepatitis C Virus (HCV)
Elagolix
Polycystic Ovary Syndrome
Upadacitinib
Ulcerative Colitis (UC)
Surabgene Lomparvovec
Diabetic Retinopathy
ombitasvir/paritaprevir/ritonavir and dasabuvir
Hepatitis C Virus (HCV)
Veliparib
Metastatic Breast Cancer
adalimumab
Pyoderma Gangrenosum
Risankizumab
Crohn's Disease (CD)
Rovalpituzumab tesirine
Small Cell Lung Cancer
ombitasvir/paritaprevir/ritonavir
Hepatitis C Infection
Tavapadon
Parkinson Disease
ABT-493 coformulated with ABT-530
Hepatitis C Virus Infection
Cariprazine
Depression
Atogepant 60 mg
Chronic Migraine
ABBV-951
Parkinson's Disease (PD)
ABT-SLV187
Advanced Parkinson's Disease
maxacalcitol
Secondary Hyperparathyroidism
BOTOX
Masseter Muscle Prominence
Corticosteroid (CS)
Giant Cell Arteritis (GCA)
Venetoclax
Acute Myeloid Leukemia (AML)
Pegylated Interferon a-2a (PegINF)
Chronic Hepatitis C Infection
Etentamig
Multiple Myeloma
ABT-493, ABT-530
Chronic Hepatitis C
Upadacitinib 15mg Dose
Atopic Dermatitis
ABT-450/r/ABT-267, ABT-333
Chronic Hepatitis C Infection
Combined Oral Contraceptive
Endometriosis
Optimized Medical Treatment
Advanced Parkinson's Disease
ABT-530
Chronic Hepatitis C
Surabgene Lomparvovec (ABBV-RGX-314)
Neovascular Age-related Macular Degeneration
LUMIGAN
Open-Angle Glaucoma
Ranibizumab (LUCENTIS®)
AMD
Optimized antiparkinsonian treatment
Parkinson's Disease (PD)
Lutikizumab
Hidradenitis Suppurativa
ABT-712
Chronic Low Back Pain
Telisotuzumab vedotin
Non-small Cell Lung Cancer
Emraclidine
Schizophrenia
ABBV-8E12
Alzheimer's Disease
ABT-450
Hepatitis C Virus
ABBV-382
Crohn's Disease
ABT-981
Erosive Hand Osteoarthritis
Ranibizumab
Neovascular Age-Related Macular Degeneration (nAMD)
ABBV-142
Idiopathic Pulmonary Fibrosis
hydrocodone/acetaminophen extended release
Chronic Low Back Pain
atomoxetine
Attention-Deficit/Hyperactivity Disorder
ABT-869
Advanced Hepatocellular Carcinoma
ABBV-6628
Geographic Atrophy
ABT-450/ritonavir (r)
Chronic Hepatitis C
Depatuxizumab mafodotin
Glioblastoma
ABBV-453
Multiple Myeloma
Ravagalimab 600 mg
Ulcerative Colitis (UC)
Leuprorelin Acetate Depot
Endometriosis
ABBV-932
Generalized Anxiety Disorder (GAD)
ABT-414
Malignant Glioma
Ombitasvir/ABT-450/Ritonavir
Chronic Hepatitis C
ABT-126
Schizophrenia
Topical Steroid
Diabetic Retinopathy (DR)
Icalcaprant
Major Depressive Disorder
Ibrutinib
Mantle Cell Lymphoma (MCL)
Emraclidine 15 mg
Schizophrenia
ABT-267
Chronic Hepatitis C
ABBV-3067
Cystic Fibrosis
ABT-199 (Main Cohort)
Chronic Lymphocytic Leukemia
CVL-871 1.0 mg
Apathy in Dementia
IMGN632
Acute Myeloid Leukemia
ABBV-916
Alzheimer's Disease (AD)
Modified FOLFIRI
Untreated Metastatic Colorectal Cancer
Darigabat
Panic Disorder
AGN-151597
Advanced Retinitis Pigmentosa
ABBV-3373
Rheumatoid Arthritis (RA)
Eluxadoline
Irritable Bowel Syndrome
Pneumococcal 13-valent conjugate vaccine (PCV-13)
Rheumatoid Arthritis
AGN-193408 SR
Open-angle Glaucoma
MEDI0618
Migraine
ABT-719
Acute Kidney Injury
ABBV-706
Small Cell Lung Cancer
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Endometriosis
ABT-199
Acute Myelogenous Leukemia
ABT-072
Hepatitis C Virus Infection
Ritonavir
Chronic Hepatitis C Infection
ABT-894
Diabetic Neuropathic Pain
ABT-494
Crohn's Disease
ABT-263
Chronic Lymphoid Leukemia
ABBV-400
Unresectable Metastatic Colorectal Cancer
Ravagalimab
Rheumatoid Arthritis
ABT-089
Attention Deficit Hyperactivity Disorder
Elsubrutinib
Systemic Lupus Erythematosus (SLE)
elezanumab
Multiple Sclerosis (MS)
CVL-865
Seizures
AGN-151607
Post-Operative Atrial Fibrillation
ABT-122
Rheumatoid Arthritis
azacitadine
Non-Hodgkin Lymphoma (NHL)
ABBV-552
Alzheimer's Disease (AD)
ABBV-668
Ulcerative Colitis
Lubricating Eye Drops
Recurrent Ovarian Cancer
CVL-231 30 mg
Schizophrenia
Risankizumab 600 mg IV
Crohn Disease
AGN-151607-DP
Ventral Hernia
TNB-383B
Multiple Myeloma
IMGN151
Gynecologic Cancers
Emraclidine 10 mg
Schizophrenia
Lenvatinib
Hepatocellular Carcinoma
0.5 mg estradiol / 0.1 mg norethindrone acetate
Heavy Uterine Bleeding
Panitumumab
Metastatic Colorectal Cancer
ABBV-383 (Etentamig)
Immunoglobulin Light Chain (AL) Amyloidosis
Atrasentan
Nephropathy
AGN-242428
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bimatoprost SR | Phase 3 | Open-Angle Glaucoma | - | - |
ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Ubrogepant | Phase 3 | Migraine | - | - |
Estradiol/Norethindrone Acetate | Phase 3 | Endometriosis | - | - |
Paricalcitol | Phase 3 | Chronic Kidney Disease Stage 3 and 4 | - | - |
Dasabuvir | Phase 3 | Chronic Hepatitis C Infection | - | - |
ABT-493/ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
Palivizumab | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
secukinumab | Phase 3 | Psoriasis | - | - |
Telaprevir | Phase 3 | Chronic Hepatitis C Infection | - | - |
Glecaprevir/Pibrentasvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Ubrogepant 100 mg | Phase 3 | Migraine | - | - |
sofosbuvir (SOF) | Phase 3 | Chronic Hepatitis C Virus | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Upadacitinib (ABT-494) | Phase 3 | Ulcerative Colitis (UC) | - | - |
etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis | - | - |
ABT-493 | Phase 3 | Chronic Hepatitis C | - | - |
OnabotulinumtoxinA | Phase 3 | Forehead Lines | - | - |
Standard of Care | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
AGN-190584 | Phase 3 | Presbyopia | - | - |
Topical corticosteroids (TCS) | Phase 3 | Atopic Dermatitis | - | - |
Risankizumab SC | Phase 3 | Crohn's Disease | - | - |
Dalbavancin | Phase 3 | Methicillin-Resistant Staphylococcus Aureus | - | - |
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Telisotuzumab Adizutecan | Phase 3 | Non-Small Cell Lung Cancer | - | - |
OBV/PTV/r | Phase 3 | Chronic Hepatitis C Virus | - | - |
AGN-151586 | Phase 3 | Glabellar Lines | - | - |
Atogepant | Phase 3 | Chronic Migraine | - | - |
Estradiol /norethindrone acetate (E2/NETA) | Phase 3 | Heavy Menstrual Bleeding | - | - |
Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma | - | - |
Botulinum Toxin Type A | Phase 3 | Masseter Muscle Prominence | - | - |
Best Available Therapy (BAT) | Phase 3 | Myelofibrosis (MF) | - | - |
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Phase 3 | Irritable Bowel Syndrome With Constipation | - | - |
ABBV-444 | Phase 3 | Dry Eye Disease | - | - |
Linaclotide | Phase 3 | Functional Constipation (FC) | - | - |
Trifluridine/Tipiracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
Navitoclax | Phase 3 | Myelofibrosis (MF) | - | - |
Tocilizumab | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
Armour Thyroid | Phase 3 | Hypothyroidism | - | - |
ABT-874 | Phase 3 | Plaque Psoriasis | - | - |
Antidepressant Therapy (ADT) | Phase 3 | Major Depressive Disorder | - | - |
Leuprolide Acetate (LA) | Phase 3 | Central Precocious Puberty (CPP) | - | - |
risankizumab IV | Phase 3 | Crohn Disease | - | - |
Fumaderm | Phase 3 | Psoriasis | - | - |
Fluvoxamine maleate | Phase 3 | Obsessive Compulsive Disorder | - | - |
Open-label Adalimumab | Phase 3 | Axial Spondyloarthritis | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
ombitasvir/paritaprevir/ritonavir, dasabuvir | Phase 3 | Chronic Hepatitis C Virus (HCV Infection Genotype 1) | - | - |
2 DAA | Phase 3 | HCV | - | - |
Topiramate | Phase 3 | Migraine | - | - |
Livmoniplimab | Phase 3 | Hepatocellular Carcinoma | - | - |
Budigalimab | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | - | - |
Cariprazine Flexible Dose | Phase 3 | Schizophrenia | - | - |
ABT-450/r/ABT-267 | Phase 3 | Hepatitis C Virus Infection | - | - |
Glecaprevir/Pibrentasvir Adult Formulation | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Glecaprevir/Pibrentasvir (GLE/PIB) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Elagolix | Phase 3 | Polycystic Ovary Syndrome | - | - |
Upadacitinib | Phase 3 | Ulcerative Colitis (UC) | - | - |
Surabgene Lomparvovec | Phase 3 | Diabetic Retinopathy | - | - |
ombitasvir/paritaprevir/ritonavir and dasabuvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Veliparib | Phase 3 | Metastatic Breast Cancer | - | - |
adalimumab | Phase 3 | Pyoderma Gangrenosum | - | - |
Risankizumab | Phase 3 | Crohn's Disease (CD) | - | - |
Rovalpituzumab tesirine | Phase 3 | Small Cell Lung Cancer | - | - |
ombitasvir/paritaprevir/ritonavir | Phase 3 | Hepatitis C Infection | - | - |
Tavapadon | Phase 3 | Parkinson Disease | - | - |
ABT-493 coformulated with ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
Cariprazine | Phase 3 | Depression | - | - |
Atogepant 60 mg | Phase 3 | Chronic Migraine | - | - |
ABBV-951 | Phase 3 | Parkinson's Disease (PD) | - | - |
ABT-SLV187 | Phase 3 | Advanced Parkinson's Disease | - | - |
maxacalcitol | Phase 3 | Secondary Hyperparathyroidism | - | - |
BOTOX | Phase 3 | Masseter Muscle Prominence | - | - |
Corticosteroid (CS) | Phase 3 | Giant Cell Arteritis (GCA) | - | - |
Venetoclax | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Pegylated Interferon a-2a (PegINF) | Phase 3 | Chronic Hepatitis C Infection | - | - |
Etentamig | Phase 3 | Multiple Myeloma | - | - |
ABT-493, ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
Upadacitinib 15mg Dose | Phase 3 | Atopic Dermatitis | - | - |
ABT-450/r/ABT-267, ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Combined Oral Contraceptive | Phase 3 | Endometriosis | - | - |
Optimized Medical Treatment | Phase 3 | Advanced Parkinson's Disease | - | - |
ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
LUMIGAN | Phase 3 | Open-Angle Glaucoma | - | - |
Ranibizumab (LUCENTIS®) | Phase 3 | AMD | - | - |
Optimized antiparkinsonian treatment | Phase 3 | Parkinson's Disease (PD) | - | - |
Lutikizumab | Phase 3 | Hidradenitis Suppurativa | - | - |
ABT-712 | Phase 3 | Chronic Low Back Pain | - | - |
Telisotuzumab vedotin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Emraclidine | Phase 2 | Schizophrenia | - | - |
ABBV-8E12 | Phase 2 | Alzheimer's Disease | - | - |
ABT-450 | Phase 2 | Hepatitis C Virus | - | - |
ABBV-382 | Phase 2 | Crohn's Disease | - | - |
ABT-981 | Phase 2 | Erosive Hand Osteoarthritis | - | - |
Ranibizumab | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
ABBV-142 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
hydrocodone/acetaminophen extended release | Phase 2 | Chronic Low Back Pain | - | - |
atomoxetine | Phase 2 | Attention-Deficit/Hyperactivity Disorder | - | - |
ABT-869 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
ABBV-6628 | Phase 2 | Geographic Atrophy | - | - |
ABT-450/ritonavir (r) | Phase 2 | Chronic Hepatitis C | - | - |
Depatuxizumab mafodotin | Phase 2 | Glioblastoma | - | - |
ABBV-453 | Phase 2 | Multiple Myeloma | - | - |
Ravagalimab 600 mg | Phase 2 | Ulcerative Colitis (UC) | - | - |
Leuprorelin Acetate Depot | Phase 2 | Endometriosis | - | - |
ABBV-932 | Phase 2 | Generalized Anxiety Disorder (GAD) | - | - |
ABT-414 | Phase 2 | Malignant Glioma | - | - |
Ombitasvir/ABT-450/Ritonavir | Phase 2 | Chronic Hepatitis C | - | - |
ABT-126 | Phase 2 | Schizophrenia | - | - |
Topical Steroid | Phase 2 | Diabetic Retinopathy (DR) | - | - |
Icalcaprant | Phase 2 | Major Depressive Disorder | - | - |
Ibrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | - | - |
Emraclidine 15 mg | Phase 2 | Schizophrenia | - | - |
ABT-267 | Phase 2 | Chronic Hepatitis C | - | - |
ABBV-3067 | Phase 2 | Cystic Fibrosis | - | - |
ABT-199 (Main Cohort) | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
CVL-871 1.0 mg | Phase 2 | Apathy in Dementia | - | - |
IMGN632 | Phase 2 | Acute Myeloid Leukemia | - | - |
ABBV-916 | Phase 2 | Alzheimer's Disease (AD) | - | - |
Modified FOLFIRI | Phase 2 | Untreated Metastatic Colorectal Cancer | - | - |
Darigabat | Phase 2 | Panic Disorder | - | - |
AGN-151597 | Phase 2 | Advanced Retinitis Pigmentosa | - | - |
ABBV-3373 | Phase 2 | Rheumatoid Arthritis (RA) | - | - |
Eluxadoline | Phase 2 | Irritable Bowel Syndrome | - | - |
Pneumococcal 13-valent conjugate vaccine (PCV-13) | Phase 2 | Rheumatoid Arthritis | - | - |
AGN-193408 SR | Phase 2 | Open-angle Glaucoma | - | - |
MEDI0618 | Phase 2 | Migraine | - | - |
ABT-719 | Phase 2 | Acute Kidney Injury | - | - |
ABBV-706 | Phase 2 | Small Cell Lung Cancer | - | - |
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) | Phase 2 | Endometriosis | - | - |
ABT-199 | Phase 2 | Acute Myelogenous Leukemia | - | - |
ABT-072 | Phase 2 | Hepatitis C Virus Infection | - | - |
Ritonavir | Phase 2 | Chronic Hepatitis C Infection | - | - |
ABT-894 | Phase 2 | Diabetic Neuropathic Pain | - | - |
ABT-494 | Phase 2 | Crohn's Disease | - | - |
ABT-263 | Phase 2 | Chronic Lymphoid Leukemia | - | - |
ABBV-400 | Phase 2 | Unresectable Metastatic Colorectal Cancer | - | - |
Ravagalimab | Phase 2 | Rheumatoid Arthritis | - | - |
ABT-089 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Elsubrutinib | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
elezanumab | Phase 2 | Multiple Sclerosis (MS) | - | - |
CVL-865 | Phase 2 | Seizures | - | - |
AGN-151607 | Phase 2 | Post-Operative Atrial Fibrillation | - | - |
ABT-122 | Phase 2 | Rheumatoid Arthritis | - | - |
azacitadine | Phase 2 | Non-Hodgkin Lymphoma (NHL) | - | - |
ABBV-552 | Phase 2 | Alzheimer's Disease (AD) | - | - |
ABBV-668 | Phase 2 | Ulcerative Colitis | - | - |
Lubricating Eye Drops | Phase 2 | Recurrent Ovarian Cancer | - | - |
CVL-231 30 mg | Phase 2 | Schizophrenia | - | - |
Risankizumab 600 mg IV | Phase 2 | Crohn Disease | - | - |
AGN-151607-DP | Phase 2 | Ventral Hernia | - | - |
TNB-383B | Phase 2 | Multiple Myeloma | - | - |
IMGN151 | Phase 2 | Gynecologic Cancers | - | - |
Emraclidine 10 mg | Phase 2 | Schizophrenia | - | - |
Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
0.5 mg estradiol / 0.1 mg norethindrone acetate | Phase 2 | Heavy Uterine Bleeding | - | - |
Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
ABBV-383 (Etentamig) | Phase 2 | Immunoglobulin Light Chain (AL) Amyloidosis | - | - |
Atrasentan | Phase 2 | Nephropathy | - | - |
AGN-242428 | Phase 2 | Dry Eye Disease | - | - |
immunology
1 drug in this indication
psoriasis
1 drug in this indication
acute and chronic hepatitis C virus (HCV)
1 drug in this indication
anti-wrinkle therapy
1 drug in this indication
Dry Eye Disease
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Open-Angle Glaucoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AbbVie Inc.'s drug pipeline?→
CatalystAlert tracks 164 drug candidates in AbbVie Inc.'s (ABBV) pipeline across Phase 3, Phase 2. Its lead program is Bimatoprost SR (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AbbVie Inc.'s next FDA catalyst?→
AbbVie Inc.'s (ABBV) next tracked catalyst is a Phase 3 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABBV biotech catalysts?→
Add ABBV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbbVie Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.